Skip to main content

Myriad Cancer Gene Test Survives, But Stock Sinks 13%

For gene-based cancer test maker Myriad Genetics, the high-court ruling that human DNA cannot be patented is killing the stock. Myriad Genetics (MYGN) stock has lost more than 13% of its value just today, to $27.73, following Thursday’s ruling from the U. S. Supreme Court that human genes cannot be patented. Myriad owns two patents related to [...]
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.